Skip to main content
. 2023 Jan 13;15(1):57–65. doi: 10.3390/hematolrep15010006

Figure 2.

Figure 2

Kaplan-Meier curves from reconstructed patient-level data. These four survival curves were obtained by reconstruction of individual patient data from four trials: melflufen plus dexamethasone (HORIZON), isatuximab plus desamethasone (NCT01084252), selinexor (STORM), and belantamab (DREAMM-2). The cohort given melflufen plus dexamethasone consisted of 119 patients, (O-12-M1 N = 119); the cohort given isatuximab plus desamethasone consisted of 55 patients, (NCT01084252 N = 55); the cohort given selinexor consisted of 122 patients (STORM = 122); and the cohort given belantamab consisted of 97 patients (DREAMM-2 = 97). Symbols: isatuximab plus dexamethasone in red, melflufen plus dexamethasone in green, selinexor in blue, belantamab in purple; time is expressed in months.